Hera Women's Health Highlights Sera Prognostics PRIME Trial Results Led by Brian K. Iriye, MD Showing Biomarker-Guided Care Improves Newborn Outcomes and Reduces NICU Use

Core Insights - Preterm birth is viewed as an avoidable high-risk event that can be anticipated and managed proactively, with a focus on earlier detection and standardized care pathways to reduce neonatal harm [1][3] - The PRIME trial demonstrated that a screen-guided approach can significantly reduce NICU admissions and improve neonatal outcomes, emphasizing the importance of proactive, outcomes-driven maternity care [2][3] Company Overview - Hera Women's Health is a national collaborative focused on providing advanced, personalized care for women, emphasizing data-driven, outcome-oriented practices [4] - The company aims to enhance healthcare outcomes by facilitating collaboration between Obstetrics and Maternal Fetal Medicine providers through evidence-based protocols and technology [4] PRIME Trial Findings - The PRIME trial involved 5018 participants across 19 sites and showed a 20% reduction in the composite neonatal morbidity/mortality index and shorter neonatal hospital stays [5] - The screen-guided approach resulted in fewer NICU admissions (10.2% vs 12.8%) and a total of 58 fewer NICU admissions and 545 fewer NICU days in the screen-guided arm [5] Competitive Advantage - Hera Women's Health has achieved a 25% reduction in preterm births and a 40% reduction in cesarean deliveries compared to regional competitors, highlighting its effective approach to maternity care [3]